BTX's logo.
Ticker Symbol: BTX

Brooklyn ImmunoTherapeutics Inc

$7.72 - 22-07-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0000748592

Company Profile

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Sector: Information
Industry: Television Broadcasting
Standard Industrial Classification Code (SIC code): 4833
Address: N/A
CEO: N/A
Tags:
  • Health Technology
  • Medical Specialties
  • Biotechnology

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $0.18 - $4.10
Beta: 1.59
52wk. High: $202.00
52wk. Low: $3.40
Ytd. Change -95.08%
50 Day Moving Average: $5.81
200 Day Moving Average: $13.38
Shares Outstanding: 58825739

Valuation

Market Cap: 24.1B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A